Point-of-Care Molecular Diagnostics Key Players and Innovation and Product Evolution

Top Companies in the Market and Recent Development

• Abbott Laboratories
• Roche Diagnostics
• Danaher Corporation
• bioMérieux
• Hologic, Inc.
• Thermo Fisher Scientific
• Qiagen
• QuidelOrtho
• LumiraDx
• Mesa Biotech
• Molbio Diagnostics
• Becton, Dickinson and Company (BD)
• Meridian Bioscience
• Binx Health
• Biocartis
• Abbott ID NOW
• Seegene
• GenMark Diagnostics
• MGI / BGI
• Newer entrants / CRISPR-NAAT specialists

Market Growth

The global point-of-care molecular diagnostics market size is calculated at US$ 4.05 billion in 2024, grew to US$ 4.48 billion in 2025, and is projected to reach around US$ 11.03 billion by 2034. The market is expanding at a CAGR of 10.45% between 2025 and 2034.

What are the Major Market Trends?

Growing innovations: The industries and institutes are contributing to the growing research and development, which is increasing the number of innovations. Advanced technologies are also being used for their development. Hence, to leverage these technologies, there is a rise in the number of acquisitions. This is being supported by the growing investments from the private sector.

For instance,

• In January 2025, to transform the rapid point-of-care diagnostics, €4.6M in equity financing was received by Novus Diagnostics. The development of a pioneering rapid point-of-care diagnostic technology platform will be accelerated by this funding, where the round was led by Irrus Investments, BVP Investments, and Trinity Biotech.
• In October 2024, the acquisition of all assets of Sensible Diagnostics Inc. was announced by Access Genetics dba OralDNA® Labs. To provide affordability and speed, with an intention to introduce a new point-of-care molecular diagnostic standard through this acquisition, along with the aim to provide central lab-quality test results within 10 minutes or less, from swabs and saliva.

Market Value Chain Analysis

R&D

The R&D of point-of-care molecular diagnostics includes the development of multiplexing tests and advancements in miniaturization, microfluidics, and nanotechnology, and is focusing on improving their accuracy and speed.

Key players: Roche, Abbott, Cepheid

Distribution to Hospitals, Pharmacies

Different types of kits and materials, such as consumables, test cartridges, swabs, vials, etc., of point-of-care molecular diagnostics are distributed to the hospitals and pharmacies.

Key players: Abbott, Cepheid, BioFire

Patient Support and Services

The patient support and services provided through point-of-care molecular diagnostics include fast results, easy use, enhanced accessibility, remote monitoring, and at-home testing.

Key players: Abaxis, Accel Diagnostics, Altratech

Latest Announcements by Industry Leaders

In June 2025, the molecular diagnostics strategy will be refocused by QuidelOrtho Corporation, where its president and chief executive officer, Brian J. Blaser, stated that, to drive shareholder value, they have been continuously reviewing their strategy for around a year since joining. To realign their product portfolio and enhance future growth, a significant step was announced. They are focusing on enhancing their presence in point-of-care molecular diagnostics, which is one of the fastest and largest growing segments in the diagnostics industry, with their intended acquisition of LEX Diagnostics.

Recent Developments in the Point-of-Care Molecular Diagnostics Market

• In August 2025, successful detection of an investigational prototype for Mycobacterium tuberculosis (MTB) on the SeekIt™ platform of Seek Labs, which is a biotech company focusing on point-of-care diagnostics, AI-powered discovery, and programmable therapeutics, was announced. Within 60 minutes, accurate results were provided by this MTB SeekIt test.
• In June 2025, the Lodestar DX testing system, which is a rapid molecular diagnostic platform for urinary tract infections (UTIs) developed by Llusern Scientific, which is a point-of-care diagnostics company, received ISO 13485 certification. With the use of Lodestar DX, clinicians can diagnose and rule out infections in a single visit with precision.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com